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Abstract 
Background: Macrophages are sentinel cells essential for tissue homeostasis and host defence. Owing to their 
plasticity, macrophages acquire a range of functional phenotypes in response to microenvironmental stimuli, of 
which M(IFN-γ) and M(IL-4/IL-13) are well known for their opposing pro- and anti-inflammatory roles. Enhancers have 
emerged as regulatory DNA elements crucial for transcriptional activation of gene expression.
Results: Using cap analysis of gene expression and epigenetic data, we identify on large-scale transcribed enhanc-
ers in bone marrow-derived mouse macrophages, their time kinetics, and target protein-coding genes. We observe 
an increase in target gene expression, concomitant with increasing numbers of associated enhancers, and find that 
genes associated with many enhancers show a shift towards stronger enrichment for macrophage-specific biological 
processes. We infer enhancers that drive transcriptional responses of genes upon M(IFN-γ) and M(IL-4/IL-13) mac-
rophage activation and demonstrate stimuli specificity of regulatory associations. Finally, we show that enhancer 
regions are enriched for binding sites of inflammation-related transcription factors, suggesting a link between stimuli 
response and enhancer transcriptional control.
Conclusions: Our study provides new insights into genome-wide enhancer-mediated transcriptional control of mac-
rophage genes, including those implicated in macrophage activation, and offers a detailed genome-wide catalogue 
of transcribed enhancers in bone marrow-derived mouse macrophages.
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Background
Macrophages are innate immune system sentinel cells 
that mediate homeostatic and protective functions, 
including host defence against invading pathogens [1]. 
Macrophages respond to a wide range of external stimuli 
by acquiring heterogeneous activation states that exert 
functional programmes tailored for specific microenvi-
ronments [2]. A spectrum of macrophage phenotypes has 
been observed, with macrophages activated in response 
to interferon-γ, M(IFN-γ), and interleukin-4/interleu-
kin-13, M(IL-4/IL-13), representing two extreme states 
[3, 4].
M(IFN-γ), often referred to as classically activated 
macrophages, is pro-inflammatory macrophages charac-
terized by efficient antigen presentation, high bactericidal 
activity and production of pro-inflammatory cytokines, 
reactive oxygen and nitrogen intermediates [5, 6]. 
M(IL-4/IL-13), often classified as alternatively activated 
macrophages, is predominantly regulatory macrophages 
involved in homeostasis, angiogenesis, wound healing, 
tissue remodelling and parasitic and bacterial infection 
[1, 2, 7–9]. M(IL-4/IL-13) macrophages release anti-
inflammatory cytokines and show less efficient antigen 
presentation and decreased production of pro-inflamma-
tory cytokines [2, 7]. Macrophage activation is driven by 
specific transcriptional changes and is controlled by com-
plex cellular mechanisms [6, 10].
Imbalance in populations of macrophages with oppos-
ing pro- and anti-inflammatory roles has been implicated 
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in disease progression [1]. Intracellular pathogen Myco-
bacterium tuberculosis, the causative agent of tubercu-
losis, interferes with classical activation of macrophages 
to avoid its antibacterial action and promotes alternative 
activation state [11, 12]. Tumour microenvironments 
promote phenotypic switches from pro- to anti-inflam-
matory macrophages, which might contribute to the 
tumour progression by inhibiting immune responses 
to tumour antigens [1, 2]. Conversely, the phenotypic 
switch from anti- to pro-inflammatory population of 
macrophages might contribute to obesity and metabolic 
syndrome [1, 2, 13]. Therefore, the development of tech-
niques for manipulation and specific targeting of mac-
rophage populations could ultimately improve diagnosis 
and treatment of inflammatory diseases [2]. To advance 
this area of research, the cellular mechanisms responsible 
for macrophage activation need to be further deciphered.
Gene expression in eukaryotic cells is a complex pro-
cess guided by a multitude of mechanisms [14]. Pre-
cise regulation is required to ensure dynamic control 
of tissue-specific gene expression and to fine tune the 
responses to external stimuli [15]. One such level of con-
trol is facilitated via regulation of RNA transcription. 
This process is mediated by a complex transcriptional 
machinery with its components recognizing specific 
regulatory regions of DNA. Promoters represent a bet-
ter-characterized class of such regions from which RNA 
transcription is initiated [16, 17]. They act in concert with 
other cis-regulatory DNA elements, including enhanc-
ers, which are believed to play key roles in transcriptional 
regulation [18].
Enhancers are defined as regulatory DNA regions that 
activate transcription of target genes in a distance- and 
orientation-independent manner [18]. According to the 
dominant model, transcriptional regulation by enhanc-
ers is exerted via direct physical interaction between 
enhancer and target gene promoter mediated by DNA 
looping [18, 19]. Recent identification of distinct prop-
erties of enhancer regions enabled novel approaches 
to enhancer profiling [18]. Enhancer regions are often 
distinguished by a specific combination of chromatin 
marks present at these locations, such as H3K4me1 and 
H3K27ac [20, 21]. Enhancer sequences contain tran-
scription factor binding sites (TFBSs) that recruit tran-
scription factors (TFs) to regulate target genes [22, 23]. 
In addition, enhancers are frequently bound by proteins 
such as histone acetyltransferase p300 and insulator-
binding protein CTCF [21, 24–26]. Large-scale profiling 
of these enhancer-associated signatures by chromatin 
immunoprecipitation followed by sequencing (ChIP-seq) 
[26, 27] has greatly advanced enhancer identification and 
enabled systematic and genome-wide enhancer mapping 
[28, 29]. Another group of methods such as chromosome 
conformation capture (3C) [30] and its variant Hi-C 
[31] has been employed to profile physical DNA con-
tacts, including those between promoters and enhancers 
[32, 33]. However, none of these methods has become a 
gold standard of enhancer detection, and the field is still 
actively developing.
Recent studies have led to the unexpected finding that 
most active enhancers recruit RNA polymerase II and 
are bidirectionally and divergently transcribed to pro-
duce RNA transcripts, referred to as eRNAs [34, 35]. 
While the functionality of eRNA remains controversial, a 
recent study by Hon et al. showed that many enhancers 
are transcribed into potentially functional long-noncod-
ing RNAs (lncRNAs) playing a role in inflammation and 
immunity [36, 37]. Recently, quantification of eRNA tran-
scription laid the foundation for a novel method of large-
scale enhancer profiling [38]. In their study utilizing cap 
analysis of gene expression (CAGE) [39], Andersson et al. 
[38] performed genome-wide mapping of transcriptional 
events followed by identification of enhancers based on 
co-occurrence of closely located divergent transcripts 
representing eRNAs. The capacity of CAGE to simul-
taneously profile the expression of eRNAs and genes 
became an additional advantage, since eRNA production 
was shown to positively correlate with the production of 
mRNAs of target genes [34, 40].
These and other studies unravelled the fundamental 
importance of enhancer regions as DNA regulatory ele-
ments in multiple cell types, including macrophages [28, 
29, 35, 40, 41]. Enhancers are extremely widespread, with 
an estimation of up to one million enhancers in mam-
malian genomes [20, 23, 24, 42]. They are major deter-
minants of gene expression programmes required for 
establishing cell-type specificity and mediating response 
to extracellular signals [23, 43, 44]. Our current under-
standing of these elements, however, remains incomplete. 
High tissue specificity of enhancers is a major hurdle 
towards establishing a comprehensive catalogue of the 
full enhancer population [23, 43]. Moreover, emerg-
ing evidence indicates that enhancers selectively act in a 
stimuli- or condition-specific manner [45, 46]. A major 
challenge is, therefore, to catalogue enhancers active in 
different tissues and conditions and link them to target 
genes.
Recently, we investigated the transcriptional regula-
tory dynamics of protein-coding and lncRNA genes 
during M(IFN-γ) and M(IL-4/IL-13) macrophage acti-
vation using CAGE data [10]. We showed that particu-
lar TFs, such as Nfκb1, Rel, Rela, Irf1, and Irf2, drive 
macrophage activation and are commonly activated 
but have distinct dynamics in M(IFN-γ) and M(IL-4/
IL-13) macrophages [10]. Here, we extended the for-
mer study to understand the regulatory influence of 
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enhancers in the macrophage activation process. Our 
genome-wide in silico study aimed at characterizing the 
transcribed enhancer landscape in mouse bone marrow-
derived macrophages (BMDM) and studying its dynamic 
changes during M(IFN-γ) and M(IL-4/IL-13) activation. 
We used CAGE data and enhancer-associated chroma-
tin signature to identify transcribed enhancer regions. 
We inferred regulatory associations between enhanc-
ers and target protein-coding genes using their spatial 
organization in topologically associating domains (TADs) 
[47] and correlation of CAGE-derived expression in our 
time course. With these data, we established a catalogue 
of transcribed enhancer regions linked to their target 
genes. This catalogue provides insights into genome-wide 
enhancer-mediated regulation of transcription in mouse 
BMDM. Furthermore, we highlight the role of enhancers 
during macrophage activation and report enhancers driv-




Mouse genomic coordinates (mm10) and tag counts of 
CAGE transcription start sites (TSSs) were obtained 
from the FANTOM5 project [17] data repository [48]. 
Data for 969 mouse samples classified as “primary_cell”, 
“time course”, “tissue”, and “cell_line” were used. The set 
included 184 BMDM samples profiled by us as described 
elsewhere [10], which we used here to construct a mac-
rophage enhancer–promoter interactome (see Additional 
file 1: Table S1 for the list of macrophage samples).
The DPI programme [49] was used as described in For-
rest et al. [17] to cluster CAGE TSSs into CAGE peaks. 
Briefly, the algorithm uses independent component 
analysis to decompose regions with continuous CAGE 
signals into separate peaks based on their profile across 
different samples and tissues. With the default parame-
ters, similarly to Forrest et al. [17], we obtained a list of 
all CAGE peaks and a subset of CAGE peaks enriched for 
promoter-associated signals. The latter file represents a 
subset of peaks meeting the FANTOM5 “robust” criteria, 
with a single TSS supported by 11 or more observations 
and one or more tags per million (TPM) in at least one 
experiment [17]. These two peak sets were used for iden-
tification of enhancers and annotation of protein-coding 
gene promoters, respectively. Tag counts of all TSSs com-
posing a CAGE peak were summed up to derive a total 
tag count for that CAGE peak.
Annotation of protein‑coding gene promoters
The set of “robust” CAGE peaks derived by DPI (see 
above) was used to annotate promoters of protein-
coding genes. Ensembl gene models [50] version 75 
downloaded from the UCSC Table Browser [51] on 11 
August 2016 was used to obtain coordinates of protein-
coding transcripts and genes. We assigned a CAGE peak 
to an Ensembl protein-coding transcript if its 5′ end was 
mapped within 500 bp of the 5′ end of the transcript on 
the same strand. The transcript annotation was extended 
to gene annotation by combining the CAGE peaks asso-
ciated with all of the gene’s transcripts.
Calculation of gene and promoter expression
TMM normalization [52] of promoter tag counts was 
performed to derive normalized expression values in 
a form of tags per million (TPM). We excluded lowly 
expressed promoters from the analysis and retained 
only those with expression of at least one TPM in 10% 
of the macrophage samples. Expression of each gene was 
derived as a sum of expression of the gene’s promoters. 
The resulting set included 24,449 promoters of 10,767 
protein-coding genes.
Identification of mouse enhancers with CAGE data
The full set of 3,188,801 DPI-derived CAGE peaks was 
used for identification of mouse enhancers. CAGE peaks 
located within 500  bp of protein-coding transcript start 
sites or within 200 bp of exons were excluded based on 
the Ensembl gene models [50] version 75. This filter-
ing resulted in 1,890,465 CAGE peaks. Next, we used 
the same strategy as Andersson et  al. to infer enhancer 
regions as clusters of closely located bidirectional diver-
gent CAGE peaks and to derive the corresponding tag 
counts [38]. The resulting 42,470 regions were deemed 
mouse enhancer regions. The counts were normalized to 
tags per million (TPM) using TMM normalization pro-
cedure [52]. Enhancers with nonzero expression in at 
least 10% of our macrophage samples were deemed tran-
scribed in our macrophage samples.
Selection of enhancers regulating protein‑coding genes 
in macrophages
Enhancer-specific chromatin signatures were based on 
ChIP-seq profiling of H3K4me1 and H3K27ac histone 
marks and were obtained from a study by Ostuni et  al. 
[53]. Transcribed enhancers with at least 1  bp over-
lap with the regions inferred by Ostuni et  al. [53] were 
retained. Genomic coordinates of TADs in mouse embry-
onic stem cells were obtained from a study by Dixon 
et  al. [47]. We selected pairs of enhancers and promot-
ers where both features were entirely located within the 
same TAD. For each of these pairs, we calculated Spear-
man’s correlation coefficient between expression levels 
of enhancer eRNA and promoter across our macrophage 
samples and selected only pairs with positive correla-
tion coefficient and FDR  <  10−4 (Benjamini–Hochberg 
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[54] procedure). We considered an enhancer to regulate 
a gene if it was associated with at least one of the gene’s 
promoters. All mm9 genomic coordinates were con-
verted to mm10 using the liftOver program [55].
Gene set enrichment analysis
KEGG pathway maps [56] or GO biological process 
ontology [57] was used as sets of biological terms for 
GSEA. GO terms and associated genes were retrieved 
using the R package GO.db [58]. We used hypergeomet-
ric distribution to calculate the probability of obtaining 
the same or larger overlap between a gene set of interest 
and each biological term [59]. Derived p values were cor-
rected for multiple testing using Benjamini–Hochberg 
procedure [54]. As a background, a set of 22,543 Ensembl 
protein-coding genes (version 75) was used [50].
Identification of macrophage‑specific features
Normalized TPM expression data were used to calcu-
late a z-score for each of our 184 macrophage samples 
for each enhancer and gene by subtracting the mean and 
dividing by the standard deviation of expression values 
of the same feature in 744 FANTOM5 non-macrophage 
mouse samples (Additional file 1: Table S2), similarly to 
Yao et al. [60]. Enhancers and genes with z-score > 3 (i.e. 
expressed more than 3 standard deviations above the 
mean of the non-macrophage samples) in at least 10% of 
macrophage samples were deemed macrophage specific.
TFBS over‑representation analysis
TFBS data for mouse were obtained from ENCODE [61] 
and HT-ChIP [62]. Raw sequencing data were mapped to 
the mm10 genome build for each tissue and cell type sep-
arately, and peaks were called using MACS2 [63]. TFBS 
summits with FDR < 10−4 were retained. We used three 
different background sets: the whole set of identified 
mouse enhancers, the subset of enhancers not expressed 
in macrophages, and a set of random genomic regions 
located within TADs excluding gaps, repeated sequences, 
Ensembl coding regions, and mouse enhancers identified 
here. Gap and repeated sequence regions were obtained 
from the UCSC Table Browser [51] on 1 August 2016 
(“gap” and “rmsk” tables of mm10 database). Signifi-
cantly over-represented TFBSs were selected based on 
empirical p value < 0.01 from a Monte Carlo analysis of 
1000 trials [64]. We retained only TFBS which showed p 
value < 0.01 using all three background sets and nonzero 
expression of the corresponding TF in our macrophages 
samples.
Identification of stimuli‑responsive features
We calculated a z-score for each of 16  M(IFN-γ) and 
16 M(IL-4/IL-13) macrophage samples for each enhancer 
and gene by subtracting the mean and dividing by the 
standard deviation of expression values of the same fea-
ture in ten non-stimulated macrophage samples, similarly 
to the approach for identification of macrophage-specific 
features. Genes and enhancers with z-score > 3 in more 
than 25% of the corresponding samples were deemed 
stimuli responsive. Of our associations between stimuli-
responsive enhancers and genes (significant with posi-
tive correlation coefficient and FDR < 10−4), we selected 
those with a positive Spearman’s correlation coefficient of 
expression in the subset of either M(IFN-γ) or M(IL-4/
IL-13) samples.
Identification of marker enhancers
We aimed to infer potential activation marker enhanc-
ers that regulate marker genes specifically during 
either M(IFN-γ) or M(IL-4/IL-13) activation. To iden-
tify marker enhancers in M(IFN-γ), we first selected 
enhancers which were deemed M(IFN-γ) responsive, 
but not M(IL-4/IL-13) responsive and were associated 
with known M(IFN-γ) marker genes. Second, a z-score 
for each of 16 M(IFN-γ) samples was calculated using 
16  M(IL-4/IL-13) samples as a background. Enhancers 
with z-score > 3 in more than 25% of M(IFN-γ) samples 
were deemed potential activation marker enhancers in 
M(IFN-γ). The same strategy was used to infer activation 
marker enhancers in M(IL-4/IL-13) macrophages.
Differential expression analysis
Differential gene expression analyses were performed 
using the exact test implemented in edgeR [52], and the 
p values were adjusted for multiple hypothesis testing 
using the Benjamini–Hochberg procedure [54].
All analyses made extensive use of the BEDTools utili-
ties [65] and the R software [66].
Results
Identification of transcribed mouse macrophage 
enhancers
Active enhancers were shown to be bidirectionally tran-
scribed in mammals [34, 35], and eRNAs profiled by 
CAGE technology [39] were used before to reliably infer 
enhancer regions in human [38]. To identify transcribed 
enhancers in mouse tissue, we used the FANTOM5 col-
lection of CAGE mouse samples [17] and a strategy 
developed before [38] (see “Methods”). This approach 
yielded 42,470 mouse enhancers, with 17,752 enhanc-
ers deemed transcribed in our BMDM samples (Fig.  1a, 
“Methods”). Ostuni et al. [53] defined enhancers in mouse 
macrophages based on two histone marks (H3K4me1 
and H3K27ac) profiled by ChIP-seq before and after dif-
ferent types of macrophage stimulation. To refine our set, 
we sub-selected 11,216 (63%) CAGE-based transcribed 
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enhancers that overlapped the ChIP-seq-based enhancer 
regions (Fig.  1a, “Methods”, Additional file  2). Of these 
11,216 enhancers, only 6.4% overlap ChIP-seq-based 
enhancers that carry histone marks of poised not acti-
vated enhancers (only H3K4me1, see Additional file  2: 
Table S13), whereas the rest also carry active enhancer 
histone mark H3K27ac either before or after macrophage 
stimulation. The remaining 6536 CAGE-based enhancers 
did not overlap regions inferred by Ostuni et al. [53] and 
were excluded from further analysis. Notably, of all CAGE-
based mouse enhancers not transcribed in BMDM, only 
19% carry macrophage enhancer chromatin signatures, 
highlighting the specificity of enhancers in mouse tissues.
Macrophage enhancer–gene interactome
We aimed at studying enhancers that regulate expres-
sion of protein-coding genes in BMDM. We first identi-
fied pairs of enhancers and promoters located within 
TADs [47], since this regulation is thought to be exerted 
via direct enhancer–promoter contact [18, 19]. Thereaf-
ter, we refined these pairs using CAGE expression data 
based on the observation that eRNA and their target 
expression are positively correlated [34] (“Methods”). 
This yielded 222,870 TAD-based enhancer–promoter 
(E–P) pairs, with 64,891 pairs showing significant posi-
tive correlation of expression in macrophages (Fig.  1a). 
These correlation-based regulatory associations formed 
the basis for our further analyses and included 8667 
enhancers deemed actively transcribed in mouse BMDM. 
Interestingly, most of the TAD-based E–P pairs show 
positive expression correlation (Additional file  3: Figure 
S1a), which supports the definition of a TAD as a struc-
tural unit favouring internal regulatory interactions [67]. 
Our filtering approach further selected regulatory asso-
ciations with correlation coefficient above 0.3 (Additional 
file  3: Figure S1a), which we considered more reliable. 
The median distance between enhancers and promot-
ers in the correlation-based E–P pairs was significantly 
smaller at 191,033nt as compared to 278,735nt for all 
TAD-based pairs (Additional file 3: Figure S1b).
We further investigated associations between enhanc-
ers and target protein-coding genes (Additional file  1: 
Table S3). Of all 10,767 protein-coding genes with 
CAGE expression (see “Methods”), 4149 genes (38.5%) 
were not associated with any enhancer in our settings 
(Fig. 1b, upper panel). Given previous evidence of addi-
tive action of enhancers [18, 68], we asked whether genes 
regulated by different numbers of enhancers have dif-
ferent gene expression levels. Genes without associated 
enhancers were overall lower expressed than genes asso-
ciated with one (two-sided Wilcoxon signed-rank test p 
value < 2.2 × 10−16) or more enhancers. A steady increase 
Fig. 1 Macrophage enhancer–gene interactome. a Pipeline for identification of enhancers and enhancer–promoter associations. b Number 
and expression of genes associated with different number of enhancers. Dashed line shows median expression of genes not associated with any 
enhancer. c KEGG pathway maps significantly enriched for genes associated with a single enhancer, FDR < 0.05. d Top 15 KEGG pathway maps 
with the lowest FDR enriched for genes associated with more than 8 enhancers. In c and d next to the bars are the numbers of genes in the KEGG 
pathway covered by our gene list; dashed lines indicate FDR = 0.05
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in gene expression concomitant with higher numbers of 
associated enhancers (Fig.  1b, Kruskal–Wallis rank sum 
test p value < 2.2 × 10−16) was observed, supporting the 
model of additive enhancer action.
We further asked whether genes associated with dif-
ferent numbers of enhancers within the enhancer–gene 
interactome show functional differences. Gene set 
enrichment analysis (GSEA) was performed for gene 
sets of similar size to avoid a size-related bias (“Meth-
ods”). The 1416 genes associated with a single enhancer 
were enriched for housekeeping pathways including 
“Aminoacyl-tRNA biosynthesis” and “Ubiquitin medi-
ated proteolysis”, as well as a few inflammation-related 
pathways (Fig.  1c). In contrast, the 1358 genes associ-
ated with more than eight enhancers showed stronger 
enrichment for signalling pathways important for mac-
rophage immune function, such as “Jak-STAT signal-
ling pathway” and “Chemokine signalling pathway” 
(Fig. 1d). GSEA for 1306 genes associated with three or 
four enhancers showed enrichment for a combination of 
housekeeping and immune pathways (Additional file  1: 
Table S4). Finally, the larger set of 4149 genes not associ-
ated with any enhancer showed the strongest enrichment 
for housekeeping pathways (Additional file 1: Table S5). 
Hence, a shift towards stronger enrichment for pathways 
important for macrophage immune function was a con-
comitant of higher numbers of associated enhancers.
Macrophage‑specific expression
We opted for a similar strategy as Yao et al. [60] (“Meth-
ods”) to uncover eRNAs and genes with higher expres-
sion in macrophages as compared to other FANTOM5 
mouse tissues (further referred to as macrophage spe-
cific). We identified 1844 macrophage-specific and 8923 
non-macrophage-specific genes (Additional file  3: Fig-
ure S2). These two sets showed significant differences 
in numbers of associated enhancers, with 65.6% of 
macrophage-specific genes being associated with more 
than one enhancer, whereas this proportion dropped to 
44.7% for non-macrophage-specific genes (odds ratio 
1.99, Fisher’s exact test p value  <  2.2 ×  10−16) (Fig.  2a). 
These results were in agreement with our observation 
of stronger enrichment for macrophage-related func-
tions in genes associated with many enhancers. Similar 
to the trend observed above, both macrophage-specific 
and non-macrophage-specific genes showed higher gene 
expression concomitant with higher numbers of associ-
ated enhancers, with non-macrophage-specific genes 
Fig. 2 Macrophage-specific enhancer and gene expression. a Percentage of genes associated with different number of enhancers. b Expression of 
4739 macrophage-specific enhancer eRNAs and 1481 associated genes. c Expression of 3928 non-macrophage-specific enhancer eRNAs and 1207 
associated genes. In b and c, expression is shown in 184 macrophage and 744 non-macrophage samples; asterisks denote Wilcoxon rank sum test 
p value < 2.2 × 10−16. d Top 15 KEGG pathway maps significantly enriched for genes associated exclusively to macrophage-specific enhancers. e 
KEGG pathway maps enriched for genes associated exclusively to non-macrophage-specific enhancers with FDR < 0.05. In d and e next to the bars 
are the numbers of genes in the KEGG pathway covered by our gene list; dashed lines indicate FDR = 0.05
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showing lower expression levels than macrophage-spe-
cific ones (Additional file 3: Figure S3).
Among 8667 active enhancers, 54.7% were deemed 
macrophage specific (“Methods”), in agreement with 
known tissue specificity of enhancers [23, 42, 43]. Inter-
estingly, non-macrophage-specific enhancers still showed 
higher eRNA expression in macrophages as compared 
to the non-macrophage samples (Fig.  2c, left panel). 
This may be explained by the fact that for this analy-
sis we excluded all enhancers that showed zero eRNA 
expression in the majority of our macrophage samples 
(“Methods”).
Next, we asked whether these two enhancer sets could 
regulate genes with different functions. Genes associated 
exclusively with macrophage-specific enhancers, as well 
as genes associated exclusively with non-macrophage-
specific enhancers, were sub-selected. As expected, 
genes in the former set showed overall higher expres-
sion in macrophage samples as compared to the non-
macrophage samples (Fig.  2b, right panel). In contrast, 
expression of genes in the latter set was lower in mac-
rophage samples (Fig.  2c, right panel). Interestingly, the 
opposite was observed for non-macrophage-specific 
enhancers (Fig.  2c, left panel). Genes associated with 
macrophage-specific enhancers were enriched for both 
housekeeping and immune pathways (Fig.  2d). This 
observation reflects the fact that production of mac-
rophage-specific factors and activation of housekeeping 
processes that facilitate it might be both regulated by the 
same set of enhancers. Genes associated with non-mac-
rophage-specific enhancers were enriched for only four 
KEGG pathway maps with FDR  <  0.05 (Fig.  2e), none 
of which can be considered a typical macrophage path-
way. We obtained consistent results when we repeated 
the analysis for a subset of 500 genes with the highest 
expression in macrophages (Additional file  1: Tables S6 
and S7). Taken together, these findings demonstrate that 
most of the identified active enhancers in macrophages 
show macrophage-specific eRNA expression and regulate 
genes with macrophage specific as well as housekeeping 
functions.
Stimuli‑induced transcriptional changes
We set out to determine transcriptional changes that 
were dynamically induced in M(IFN-γ) and M(IL-4/
IL-13) mouse macrophages and to infer enhancers 
important in these processes (Fig.  3a). M(IFN-γ)- and 
M(IL-4/IL-13)-responsive enhancers and genes were 
identified as those up-regulated upon stimulation; 
regulatory associations were retained for pairs with a 
positive correlation of expression in the correspond-
ing activation state (“Methods”). In this manner, we dis-
covered 115  M(IFN-γ)-responsive enhancers regulating 
105  M(IFN-γ)-responsive genes (further referred to as 
sets E1 and G1), as well as 131 M(IL-4/IL-13)-responsive 
enhancers regulating 98 M(IL-4/IL-13)-responsive genes 
(sets E2 and G2) (Fig.  3b and Additional file  1: Tables 
S8 and S9). GSEA of G1 and G2 gene sets showed sig-
nificant enrichment for GO and KEGG terms relevant to 
immune system and macrophage functions (Fig.  3c and 
Additional file  3: Figure S4). These results highlight the 
importance of enhancer regulatory control during mac-
rophage activation and suggest a striking influence of 
cytokine stimulation on activation of enhancers, which, 
in turn, drive some of the transcriptional responses seen 
during M(IFN-γ) and M(IL-4/IL-13) activation.
To gain an understanding of the distribution of stimuli-
responsive elements in macrophage-specific and non-
specific genes and enhancers, we calculated their overlaps 
(see Additional file  3: Figure S5). We found that 15.6% 
of macrophage-specific genes and 6.8% of macrophage-
specific enhancers were also stimuli responsive. Of note, 
of all stimuli-responsive enhancers, 70.1% were also mac-
rophage specific (77% of E1 and 71% of E2 enhancers).
M(IFN-γ) and M(IL-4/IL-13) macrophages are known 
to possess different phenotypes and functions [2]. As 
expected, G1 and G2 sets had only 19 genes in com-
mon. Similarly, a small overlap of only 14 enhancers was 
observed for E1 and E2 sets. Moreover, enhancers and 
genes selected as stimuli-responsive for a single activa-
tion state showed significant differences in time-course 
expression in M(IFN-γ) and M(IL-4/IL-13) macrophages 
(Fig. 3d). These data indicate that M(IFN-γ) and M(IL-4/
IL-13) macrophages not only differ in their gene expres-
sion profiles, but also differ in their active enhancer 
repertoire that likely drives observed gene expression 
changes.
Previous studies reported and exploited positive 
expression correlation of eRNA and target genes [34, 
38, 60]. Hence, we compared expression correlation of 
E1–G1 and E2–G2 pairs in M(IFN-γ) and M(IL-4/IL-13) 
macrophages (Fig.  3e) to determine how correlations 
differ between conditions. E1–G1 pairs showed higher 
correlation in M(IFN-γ) macrophages as compared to 
M(IL-4/IL-13) (two-sided Wilcoxon signed-rank test p 
value =  1.633 ×  10−6). Similarly, correlation for E2–G2 
pairs was higher in M(IL-4/IL-13) macrophages (two-
sided Wilcoxon signed-rank test p value < 2.2 × 10−16). 
Such stimuli-specific expression correlation suggests 
stimuli specificity of enhancer–gene regulatory associa-
tions in macrophages.
Marker genes of macrophage activation are regulated 
by stimuli‑responsive enhancers
We further asked which known marker genes of classi-
cal and alternative macrophage activation [1, 2, 6, 7, 69] 
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Fig. 3 Stimuli-responsive genes and enhancers. a Time-course data used in this study. b Enhancer and gene sets. E1 and E2: M(IFN-γ)- and M(IL-4/
IL-13)-responsive enhancers regulating M(IFN-γ)- and M(IL-4/IL-13)-responsive genes (G1 and G2), respectively; E1′ and E2′: M(IFN-γ)- and M(IL-4/
IL-13)-responsive enhancers regulating non-stimuli-responsive genes; G1′ and G2′: M(IFN-γ)- and M(IL-4/IL-13)-responsive genes not regulated 
by stimuli-responsive enhancers. Black arrows denote regulatory associations between stimuli-responsive enhancers and genes; of all previously 
defined significant associations, here we retained only those with positive correlation of expression in the corresponding subset of macrophages. 
c GO biological process terms enriched for G1 and G2 genes (all terms with FDR < 0.05 for G1; six terms with the lowest FDR for G2 are shown); 
dashed lines indicate FDR = 0.05. d Expression of stimuli-responsive enhancer eRNAs (upper panel) and genes (lower panel) unique to M(IFN-γ) or 
M(IL-4/IL-13). Statistical significance was determined by Wilcoxon signed-rank test, asterisks indicate p value < 10−5. e Correlation of time-course 
expression of M(IFN-γ)-responsive (upper panel) and M(IL-4/IL-13)-responsive (lower panel) enhancers and genes. Vertical dashed lines show 
median values
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were identified in M(IFN-γ) and M(IL-4/IL-13) in our 
setting (Table  1). Among 20 examined marker genes of 
classical macrophage activation, we found eight genes in 
the G1 set; similarly, eight of examined 26 marker genes 
of alternative activation were found in the G2 set (signifi-
cant overlap with hypergeometric test p value  <  10−10) 
(Table 1). The G1′ set contained an additional four clas-
sical macrophage activation marker genes (Gpr18, Il12b, 
Il6, Inhba) and the G2′ set an additional three alterna-
tive activation marker genes (Il27ra, Klf4, Myc), which, 
although stimuli-responsive themselves, were not associ-
ated with stimuli-responsive enhancers.
Next, we investigated the enhancer regulation of these 
marker genes. Given that different enhancers can modu-
late expression of the same gene in different conditions, 
we aimed to infer potential marker enhancers that regu-
late marker genes specifically during either M(IFN-γ) or 
M(IL-4/IL-13) activation. Each of the 16 marker genes in 
G1 and G2 was associated with a minimum of one and 
maximum of nine enhancers in the E1 and E2 stimuli-
responsive sets, respectively (Table 1). Of those, we iden-
tified enhancers that were selectively responsive in a 
single activation state and showed higher eRNA expres-
sion in this state as compared to the other one (“Meth-
ods”). A total of 13  M(IFN-γ) and 22  M(IL-4/IL-13) 
enhancers were inferred as potential activation markers 
(Table 1).
Interestingly, three marker genes found in M(IFN-γ), 
Cxcl9, Cxcl10, and Cxcl11 are located within one TAD 
and are co-regulated by a group of three marker enhanc-
ers (Fig. 4a–c, see also Additional file 3: Figure S6 for a 
genome browser view of one of these enhancers). These 
enhancers, along with the two marker enhancers regu-
lating Cxcl10 or Cxcl11 but not Cxcl9 (Table  1), are 
located in close proximity, in the intronic regions of the 
Art3 gene (Fig.  4c). These enhancer regions were pre-
viously reported to show induced RNA polymerase II 
binding in macrophages upon stimulation with LPS, 
one of the known classical macrophage activators [35]. 
In addition, these marker enhancer regions were shown 
to carry H3K4me1 enhancer histone marks in untreated 
macrophages [53]. Moreover, H3K27ac modification, 
associated with active enhancers, is stronger enriched in 
these regions in M(IFN-γ) as compared to M(IL-4) and 
untreated macrophages [53] (Fig.  4c), providing further 
evidence of their functionality in macrophage M(IFN-γ) 
activation.
Among marker genes found in M(IL-4/IL-13), Arg1 
as expected is substantially expressed in M(IL-4/IL-13) 
macrophages but has extremely low expression in 
M(IFN-γ) and untreated macrophages (Additional file 3: 
Figure S7a). We found a single M(IL-4/IL-13)-respon-
sive enhancer that might drive expression of Arg1 in 
M(IL-4/IL-13) macrophages and might serve as a marker 
enhancer (Table 1 and Additional file 3: Figure S7b). On 
the contrary, marker gene Egr2 found in M(IL-4/IL-13), 
a TF that activates macrophage genes [70], is associated 
with as many as nine M(IL-4/IL-13) marker enhanc-
ers (Table  1). Egr2 showed immediate up-regulation 
in response to both IFN-γ and IL-4/IL-13 stimulation; 
however, in M(IL-4/IL-13) macrophages the up-regula-
tion sustained for up to 24 h, whereas in M(IFN-γ) mac-
rophages expression dropped rapidly after 2  h (Fig.  4d, 
upper panel). Time-course eRNA expression for two Egr2 
marker enhancers with the highest expression at 2 and 
4 h is shown in Fig. 4d. The distribution of all nine Egr2 
marker enhancers within a TAD (Fig.  4e) may suggest 
that the regions identified as nine individual enhancers 
potentially demarcate fewer regions of stretch enhancers 
[71, 72]. We observed a similar distribution for enhancers 
of marker gene Igf1, which is known to shape the alter-
natively activated macrophage phenotype and regulate 
immune metabolism [73] (Additional file  3: Figure S8, 
see also Additional file 3: Figure S9 for a genome browser 
view of one of these enhancers with the highest expres-
sion at 2 h). Importantly, in both Egr2 and Igf1, marker 
enhancer regions carried H3K4me1 in untreated mac-
rophages and showed the strongest enrichment with 
H3K27ac in M(IL-4) as compared to M(IFN-γ) and 
untreated macrophages [53] (Fig. 4e and Additional file 3: 
Figure S8c).
Transcription factor binding sites are enriched in enhancer 
regions
To investigate whether our enhancer sets are enriched 
for known transcription binding sites (TFBSs), we per-
formed an over-representation analysis of experimen-
tally determined protein DNA binding sites established 
through ChIP-seq [61, 62] (“Methods”). The sets of 
macrophage-specific and non-macrophage-specific 
enhancers are both enriched for binding sites of general 
factors (p300, Tbp), as well as a range of TFs with well-
established roles in macrophages, such as macrophage 
lineage-determining factor Spi1 (PU.1) [41, 74], Cebpb, 
required for macrophage activation [75], and Rela, regu-
lating inflammatory genes [76] (Additional file  1: Table 
S10). Interestingly, TFBSs for Spi1 overlap 54.1% of 
macrophage-specific enhancers, but only 38% of non-
macrophage-specific enhancers (overlap ratio of 1.4 for 
macrophage-specific/non-macrophage-specific enhanc-
ers). We observed similar and higher overlap ratios 
for other functionally important TFs in macrophages, 
including Stat1, Rela, Irf1, Junb, and Cebpb [6, 75–77] 
(Table  2). Six out of the seven TFs in Table  2, except 
for Junb, showed macrophage-specific expression (see 
above). Moreover, four TFs (Stat1, Irf1, Spi1, Cebpb) were 
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Fig. 4 Examples of macrophage activation marker genes and enhancers. a Expression of classically activated macrophage marker genes Cxcl9, 
Cxcl10, and Cxcl11. b eRNA expression of three potential marker enhancers that co-regulate Cxcl9, Cxcl10, and Cxcl11. c Genomic region of a TAD 
containing Cxcl9, Cxcl10, Cxcl11, and associated enhancers. Black links connect the marker genes with the three potential marker enhancers. Grey 
links denote other enhancer–gene interactions that we identified in macrophages. d Expression of alternatively activated macrophage marker gene 
Egr2 and two of M(IL-4/IL-13) marker enhancers associated with Egr2. e Genomic region of a TAD containing Egr2 and associated enhancers. Black 
links connect Egr2 with the nine M(IL-4/IL-13) marker enhancers. Grey links denote other enhancer–gene interactions that we identified in mac-
rophages. In a, b, and d, data were averaged over replicates and log-transformed. Error bars are the SEM. In c and e, genes are split into two tracks 
based on the strand, and wide orange marks denote gene promoters; histone mark tracks show ChIP-seq peaks with the height of − 10 × log10(p 
value), data from [53]
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significantly differentially expressed and up-regulated 
(FDR < 0.01,  log2FC > 2) in our 184 macrophage samples 
when compared to the 744 FANTOM5 non-macrophage 
mouse samples (“Methods”). Furthermore, we found that 
macrophage-specific enhancers associated with Rela 
(chr19:5931597…5931998, chr19:6157210…6157611) 
and Spi1 (chr2:91086328…91086729, chr2:91204688… 
91205089) also carry TFBSs of the corresponding TFs, 
suggesting the formation of enhancer-mediated positive 
feedback loops, where a TF may induce its own enhanc-
ers. A genome browser view of one of these enhanc-
ers (chr2:91086328…91086729) shows a distribution of 
TFBSs and CAGE tags in the corresponding genomic 
region, which, notably, is located within an intron of 
the enhancer target gene Spi1 (Additional file  3: Fig-
ure S10). In addition, we show a genome browser view 
for M(IFN-γ) marker enhancer with non-macrophage-
specific eRNA expression and M(IL-4/IL-13) marker 
enhancer with macrophage-specific eRNA expression 
(Additional file  3: Figures S6 and S9). Although both 
regions carry multiple TFBSs, we note that non-mac-
rophage-specific enhancers can be characterized by a 
high occurrence of general enhancer proteins Ctcf and 
Ep300, as reflected in the TFBS over-representation anal-
ysis results (Additional file 1: Table S10).
The E1 and E2 stimuli-responsive enhancer sets are 
enriched for TFBSs of known macrophage TFs includ-
ing Spi1, Cebpb, Rela, Irf, and Stat families [6, 78, 79] 
(Table  3, Additional file  1: Table S11). Interestingly, 
TFBSs of Stat1, Rela, and Irf1, involved in classical mac-
rophage activation [6, 80], overlap a higher percentage of 
E1 enhancers as compared to E2 and macrophage-spe-
cific enhancers (Tables 2, 3, and Additional file 1: Tables 
S10 and S11). For instance, Irf1 TFBSs overlap 21.7% of 
macrophage-specific enhancers, 26.7% of E2 but 44.3% 
of E1 enhancers. In addition, Stat1 and Irf1 were deemed 
M(IFN-γ) responsive and were significantly differentially 
expressed and up-regulated (FDR < 0.01,  log2FC > 1) in 
M(IFN-γ) when compared to either control or M(IL-4/
IL-13) macrophages (“Methods”). Taken together, these 
results provide an additional layer of support for our 
regions as functionally important macrophage enhancers 
and implicate key macrophage TFs in modulating their 
activity. These findings further reflect that enhancers are 
Table 2 TFs regulating more macrophage-specific than non-macrophage-specific enhancers
Columns show TF name, average expression in macrophage samples (in TPM, see “Methods”), percentage of enhancers overlapping corresponding binding sites, and 
a macrophage-specific/non-macrophage-specific percentage ratio. TFBSs are statistically significantly enriched in both enhancer sets
TF Mean TPM in macrophages % Macrophage‑specific enhancers % Non‑macrophage‑specific enhancers Ratio
Stat1 284.6 15.8 8.5 1.9
Rela 130.7 26.6 14.5 1.8
Atf4 329.4 25.5 14.3 1.8
Irf1 508.7 21.7 12.2 1.8
Junb 176.3 11.2 7.4 1.5
Spi1 599.9 54.1 38 1.4
Cebpb 647.9 48 34.8 1.4
Table 3 TFs with binding sites enriched in both E1 and E2 enhancer sets
Columns show TF name, average expression in M(IFN-γ) and M(IL-4/IL-13) macrophages (in TPM, see “Methods”), percentage of enhancers overlapping corresponding 
binding sites, and a M(IFN-γ)/M(IL-4/IL-13) percentage ratio
TF Mean TPM in M(IFN‑γ) % Enhancers in M(IFN‑γ) Mean TPM in M(IL‑4/IL‑13) % Enhancers in M(IL‑4/IL‑13) Ratio
Stat1 726.3 40.9 218.6 22.9 1.8
Irf1 1345.4 44.3 426.7 26.7 1.7
Ets1 1.4 39.1 7 25.2 1.6
Jun 74.3 14.8 70 9.9 1.5
Rela 131.6 42.6 102.8 29.8 1.4
Atf4 277.3 33.9 208.3 27.5 1.2
Junb 122 13 99.7 13 1
Irf4 2.3 13 18.7 13.7 0.9
Spi1 766.3 52.2 681.7 56.5 0.9
Cebpb 424.6 51.3 262.9 59.5 0.9
Atf3 233.9 9.6 242.9 12.2 0.8
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selectively activated depending on the transcriptional 
machinery involved in the cellular response.
Discussion
In this study, we investigated the transcribed enhancer 
landscape in mouse BMDM and its dynamic changes 
during M(IFN-γ) and M(IL-4/IL-13) activation. Using 
CAGE data combined with ChIP-seq, we identified 8667 
actively transcribed enhancers forming 64,891 regula-
tory associations with protein-coding gene promoters in 
mouse BMDM. We highlighted tissue and stimuli speci-
ficity of both enhancers and their regulatory interactions. 
The enhancer–gene interactome established here sup-
ports a model of additive action of enhancers [18, 68], 
with higher gene expression concomitant with higher 
numbers of associated enhancers. Moreover, we observed 
a shift towards stronger enrichment for signalling path-
ways important for macrophage immune function in 
genes associated with many enhancers. Cytokine stimu-
lation had a striking influence on enhancer transcrip-
tion, which highlights the importance of enhancers in 
macrophage activation. In addition, we inferred potential 
macrophage activation marker enhancers. Finally, we find 
that binding sites of inflammatory TFs are enriched in 
enhancer regions, proposing a link between the response 
to stimuli and enhancer transcriptional activation.
Several studies have previously reported on enhancer 
landscape in mouse macrophages. Different populations 
of tissue macrophages were shown to be highly hetero-
geneous and to possess distinct sets of active enhancers, 
as defined by ChIP-seq profiling of histone modifications 
[28, 29]. Studies by Ostuni et al. [53] and Kaikkonen et al. 
[40] used ChIP-seq experiments to uncover enhancers 
that were established in macrophages de novo in response 
to a range of stimuli. In contrast to previous studies, we 
combined two complementary data types, transcriptomic 
(CAGE-derived) and epigenomic (ChIP-seq-derived, 
profiled by Ostuni et al. [53]) data, to infer more reliable 
transcribed active enhancers in mouse BMDM. Ostuni 
et  al. separated macrophage enhancer regions into dif-
ferent enhancer classes based on the enhancer response 
to a range of stimuli. Our data show that in naïve mac-
rophages 31% of active ChIP-seq-based enhancers show 
transcriptional activity. Of the poised not activated ChIP-
seq enhancers, only 7.1% showed transcriptional activ-
ity in our set of 42,470 mouse enhancers. Both these 
observations support the idea of enhancer transcription 
being associated with histone-mark-based active states of 
enhancers.
Importantly, our analysis extended beyond identifica-
tion of enhancers and characterization of their nearest 
genes. Here, instead of a widely used linear proximity-
based approach [35, 38, 45], we employed TAD data to 
infer enhancer–gene associations. Accumulating evi-
dence suggests that many enhancers regulate distal genes, 
bypassing the nearest promoter [81, 82]. At the same 
time, TADs have emerged as units of chromatin organi-
zation that favour internal DNA contacts [67], and the 
majority of characterized interactions between enhanc-
ers and target promoters occur within the same TAD [67, 
82, 83]. Hence, our TAD-based approach enriched with 
correlation-based filtering enabled us to establish a more 
reliable mouse BMDM enhancer–gene interactome.
Our interactome covers 8667 actively transcribed 
enhancers. Of these, 70% overlap RNA polymerase II 
ChIP-seq peaks in untreated mouse macrophages [53]. 
Our enhancer regions show significant enrichment 
for binding sites of histone acetyltransferase p300, an 
enhancer-associated marker [26], and known inflam-
matory TFs. Hence, the regions identified here show a 
range of known enhancer properties, generally support-
ing our approach. Most of the active enhancers show 
macrophage-specific eRNA expression, in line with 
known tissue specificity of enhancers [23, 42, 43]. Kaik-
konen et al. [40] identified mouse macrophage enhancers 
using ChIP-seq against H3K4me2. Our findings based 
on CAGE-seq extend their enhancer repertoire by addi-
tional 3974 transcribed enhancer regions. A compari-
son expanded to non-macrophage enhancers shows that 
39.8% of our enhancers overlap a set of cis-regulatory 
elements from 19 non-macrophage mouse tissues identi-
fied by Shen et al. [42]. In another recent study, Schoen-
felder et  al. [33] employed a Capture Hi-C approach to 
identify enhancers and their target promoters in mouse 
foetal liver cells and embryonic stem cells. Even though 
enhancers and enhancer–promoter interactions are 
known to be highly tissue specific, their data still support 
24.8% of our 64,891 E–P pairs.
Recent reports suggested that genes regulated by multi-
ple enhancers were higher expressed than those regulated 
by a single enhancer, proposing that enhancers might 
contribute additively to the expression of their target 
genes [18, 68]. In support of this, we observed a steady 
increase in gene expression concomitant with increas-
ing numbers of associated enhancers, with the genes not 
associated with any enhancers showing the lowest overall 
expression. A study of 12 mouse tissues has reported the 
enrichment for tissue-specific functions in genes associ-
ated with enhancers that transcribe eRNAs as compared 
to genes associated with non-transcribed enhancers [84]. 
Jin et  al. recently showed that genes that did not inter-
act with distal enhancers were enriched for housekeep-
ing genes and also suggested that cell-specific genes were 
extensively controlled by cis-regulators [85]. We showed 
in this study that genes associated with many enhancers 
were more enriched for macrophage-related functions 
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as compared to genes associated with only few or no 
enhancers. This finding might reflect a more fundamental 
principle of genome organization and evolution, such as 
the importance of multiple enhancers for fine-tuned and 
redundant control of cell specialization and cell-specific 
responses.
Studies by Ostuni et al. [53] and Kaikkonen et al. [40] 
revealed stimuli-specific epigenomic changes in enhancer 
regions in mouse macrophages and introduced a concept 
of stimuli-specific enhancer activation. In our study, we 
focused on enhancers and genes that responded to the 
stimuli with increased expression in order to further 
investigate this phenomenon. Notably, many stimuli-
responsive genes were associated with stimuli-responsive 
enhancers, highlighting the importance of enhancer reg-
ulation in macrophage activation. As expected for such 
a cell-type-specific process as macrophage activation, 
most of the responsive enhancers showed macrophage-
specific eRNA expression, and genes were enriched for 
macrophage-specific functions. In addition, our study 
suggests stimuli specificity of enhancer–gene regulatory 
associations in macrophages.
As an important example, we assessed 20 and 26 
marker genes of classically and alternatively activated 
macrophages to characterize their enhancer regulation 
[1, 2, 6, 7, 69]. Of those, seven markers (Ccl20, Fpr2, Ido1; 
Chi3l3, Chi3l4, Alox12e, Chia) were not expressed in our 
data. For a total of 16 marker genes, we identified asso-
ciated enhancers. Moreover, for 11 of them we found 
enhancers that might regulate these genes specifically in 
M(IFN-γ) or M(IL-4/IL-13) stimulation (Table 1). Hence, 
these enhancers present new potential markers for a par-
ticular macrophage activation status. Seven additional 
marker genes, identified as stimuli responsive, were not 
associated with any stimuli-responsive enhancer (Gpr18, 
Il12b, Il6, Inhba in the G1′ set; Il27ra, Klf4, Myc in the 
G2′ set). The remaining marker genes were not deemed 
stimuli-responsive. Of those, classically activated mac-
rophage markers Il1b, Cd86, Marco, and Il23a and alter-
natively activated macrophage markers Mmp12, Tgm2, 
Clec4a2, Stab1, F13a1 were associated with at least one 
enhancer in macrophages. Ccr7, Retnla, Ccl17, Ccl22, 
Chi3l1, Cxcl13, and Ccl12 were not associated with any 
enhancers in macrophages.
We observed a particular genomic distribution of 
potential marker enhancers associated with Egr2 and 
Igf1 marker genes in M(IL-4/IL-13), which suggested that 
these regulatory DNA regions might represent stretch 
enhancers. Parker et  al., in a recent study, investigated 
stretch enhancers in human cells and proposed that such 
extended regions could serve as molecular runways to 
attract tissue-specific TFs and focus their activity [72]. 
Similarly to Parker et  al., potential stretch enhancer 
regions identified here were associated with cell-type 
specific genes and were demarcated by broad H3K27ac 
signals, specifically higher enriched in M(IL-4) as com-
pared to M(IFN-γ) and untreated macrophages (Fig. 4e, 
Additional file 3: Figure S8c). Therefore, we propose that 
stretch enhancers might be involved in the regulation 
of macrophage activation. However, further studies are 
required to investigate this phenomenon in more detail.
Our approach inferred M(IFN-γ)- and M(IL-4/IL-
13)-responsive enhancers that were strongly enriched 
for TFBS of known inflammatory TFs. These results are 
in line with previous reports in mouse macrophages. 
For example, Spi1 (PU.1) has been extensively studied 
as a crucial TF involved in macrophage differentiation 
and transcriptional regulation [41]. Moreover, Spi1 was 
deemed a pioneering or lineage-determining TF in mac-
rophages, which defines enhancer regions and occupies 
many enhancers in macrophages [28, 35, 41, 74]. Fur-
thermore, Heinz et al. suggested that collaborative action 
of Spi1 with Cebpb was required for the deposition of 
enhancer-associated chromatin marks [74]. Ghisletti 
et al. reported enrichment for NF-kB (Rel) and Irf TFs in 
enhancers induced by LPS in mouse macrophages [41]. 
Likewise, transcribed enhancers induced by LPS and 
IFN-γ stimulation showed enrichment for NF-kB/Rel, Irf, 
and Stat1 binding motifs [35]. In addition, we previously 
showed that TFs including Rela and Irf1 drive expression 
of protein-coding and lncRNA genes during macrophage 
activation [10]. Taken together, our results link enhancer 
activation to the transcriptional programme induced by 
IFN-γ and IL-4/IL-13 stimuli.
Conclusions
In this study, we have established a genome-wide cata-
logue of enhancers and enhancer–promoter regulatory 
interactions in mouse BMDM. In contrast to previous 
studies of enhancer landscape in mouse macrophages, 
we focused on transcribed enhancers and employed an 
improved method for identification of enhancer target 
genes, based on location within a TAD and correlation of 
expression. Hence, our study represents the most com-
prehensive analysis of transcribed enhancer activities in 
mouse macrophages to date and extends current knowl-
edge of transcriptional regulation in macrophages in gen-
eral and during activation in particular.
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